Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
- Andrew E. Teschendorff1,
- Usha Menon2,
- Aleksandra Gentry-Maharaj2,
- Susan J. Ramus2,
- Daniel J. Weisenberger3,
- Hui Shen3,
- Mihaela Campan3,
- Houtan Noushmehr3,
- Christopher G. Bell1,
- A. Peter Maxwell4,
- David A. Savage4,
- Elisabeth Mueller-Holzner5,
- Christian Marth5,
- Gabrijela Kocjan6,
- Simon A. Gayther2,
- Allison Jones2,
- Stephan Beck1,
- Wolfgang Wagner7,
- Peter W. Laird3,
- Ian J. Jacobs2 and
- Martin Widschwendter2,8
- 1 Medical Genomics Group, UCL Cancer Institute, University College London, London WC1E 6BT, United Kingdom;
- 2 Department of Gynecological Oncology, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London W1T 7DN, United Kingdom;
- 3 USC Epigenome Center, University of Southern California, Keck School of Medicine, Los Angeles, California 90089-9601, USA;
- 4 Nephrology Research Group, Centre for Public Health, Queen's University Belfast, Belfast BT9 7AB, Northern Ireland;
- 5 Department of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck 6020, Austria;
- 6 Department of Histopathology, University College London, London WC1E 6JJ, United Kingdom;
- 7 Helmholtz Institute for Biomedical Engineering–Cell Biology, Aachen University Medical School, 52074 Aachen, Germany
Abstract
Polycomb group proteins (PCGs) are involved in repression of genes that are required for stem cell differentiation. Recently, it was shown that promoters of PCG target genes (PCGTs) are 12-fold more likely to be methylated in cancer than non-PCGTs. Age is the most important demographic risk factor for cancer, and we hypothesized that its carcinogenic potential may be referred by irreversibly stabilizing stem cell features. To test this, we analyzed the methylation status of over 27,000 CpGs mapping to promoters of ∼14,000 genes in whole blood samples from 261 postmenopausal women. We demonstrate that stem cell PCGTs are far more likely to become methylated with age than non-targets (odds ratio = 5.3 [3.8–7.4], P < 10−10), independently of sex, tissue type, disease state, and methylation platform. We identified a specific subset of 69 PCGT CpGs that undergo hypermethylation with age and validated this methylation signature in seven independent data sets encompassing over 900 samples, including normal and cancer solid tissues and a population of bone marrow mesenchymal stem/stromal cells (P < 10−5). We find that the age-PCGT methylation signature is present in preneoplastic conditions and may drive gene expression changes associated with carcinogenesis. These findings shed substantial novel insights into the epigenetic effects of aging and support the view that age may predispose to malignant transformation by irreversibly stabilizing stem cell features.
Footnotes
-
↵8 Corresponding author.
E-mail m.widschwendter{at}ucl.ac.uk.
-
[Supplemental material is available online at http://www.genome.org. The microarray data from this study have been submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession nos. GSE19711, GSE20067, and GSE20080.]
-
Article published online before print. Article and publication date are at http://www.genome.org/cgi/doi/10.1101/gr.103606.109.
-
- Received November 26, 2009.
- Accepted February 11, 2010.
- Copyright © 2010 by Cold Spring Harbor Laboratory Press